Overview

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Status:
Completed
Trial end date:
2018-11-25
Target enrollment:
0
Participant gender:
All
Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Criteria
Inclusion Criteria:

- Members of families with established MAPT mutations, who either have the capacity to
consent to participate in the protocol, or else have designated a surrogate/proxy to
consent to participate in this study

Exclusion Criteria:

- Unwillingness to participate

- Usage of medication which significantly prolongs QT interval

- Pregnancy or plans for pregnancy within 90 days after participating in study